ReviewNature medicine2020
Single-cell genomic approaches for developing the next generation of immunotherapies.
Review in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 112 citations in OpenAlex.
- Identifying head and neck squamous cell carcinoma: HPV-associated signature by integrating bulk and single-cell sequencing data.Medicine · 2026Article
- Integrating gene-microbiome interactions and single-cell transcriptomics reveals therapeutic strategies for aortic aneurysm.iScience · 2026Article
- Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.Blood advances · 2026Article
- Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy response.Cancer immunology, immunotherapy : CII · 2026Article
- Article
- Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses.Frontiers in immunology · 2026Review
- Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy.Molecular cancer · 2025Review
- Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology.Molecular oncology · 2025Article
- Single-cell analysis reveals transcriptomic features and therapeutic targets in primary pulmonary lymphoepithelioma-like carcinoma.Communications biology · 2025Article
- Toti-N-glycan Recognition Enables Universal Multiplexed Single-Nucleus RNA Sequencing.Research (Washington, D.C.) · 2025Article
- Integrated multi-omics profiling reveals neutrophil extracellular traps potentiate Aortic dissection progression.Nature communications · 2024Article
- Neutrophil-based single-cell sequencing combined with transcriptome sequencing to explore a prognostic model of sepsis.Scientific reports · 2024Article
- A potential coagulation-related diagnostic model associated with immune infiltration for acute myocardial infarction.Genes and immunity · 2024Article
- A Bayesian framework for inferring dynamic intercellular interactions from time-series single-cell data.Genome research · 2024Article
- Advancements in Single-Cell RNA Sequencing and Spatial Transcriptomics for Central Nervous System Disease.Cellular and molecular neurobiology · 2024Review
- Time - The fourth dimension of immune cells.MedComm · 2024Article
- Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis.Oncogene · 2024Article
- GENIX enables comparative network analysis of single-cell RNA sequencing to reveal signatures of therapeutic interventions.Cell reports methods · 2024Article
- Article
- SCIPAC: quantitative estimation of cell-phenotype associations.Genome biology · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent progress in single-cell genomics urges its application in drug development, particularly of cancer immunotherapies. Current immunotherapy pipelines are focused on functional outcome and simple cellular and molecular readouts. A thorough mechanistic understanding of the cells and pathways targeted by immunotherapy agents is lacking, which limits the success rate of clinical trials. A large leap forward can be made if the immunotherapy target cells and pathways are characterized at high resolution before and after treatment, in clinical cohorts and model systems. This will enable rapid development of effective immunotherapies and data-driven design of synergistic drug combinations. In this Perspective, we discuss how emerging single-cell genomic technologies can serve as an engine for target identification and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.